【FINTEC 0150 交流专区】（前名 ASIABIO）

icy97

ASIA BIOENERGY TECHNOLOGIES BERHAD

1. Details of Corporate Proposal
Whether the corporate proposal involves the issuance of new type and new class of securities?	No
Types of corporate proposal	Private Placement
Details of corporate proposal	PRIVATE PLACEMENT OF UP TO 38,200,000 NEW ORDINARY SHARES OF RM0.10 EACH IN ASIABIO REPRESENTING UP TO 10% OF THE ISSUED AND PAID-UP SHARE CAPITAL OF ASIABIO
No. of shares issued under this corporate proposal	38,200,000
Issue price per share ($$)	MYR 0.100
Par Value ($$)	MYR 0.100
Latest issued and paid up share capital after the above corporate proposal in the following
Units	420,200,000
Currency	MYR 42,020,000.000
Listing Date	19/06/2013

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 30/04/2013

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30/04/2013	30/04/2012	30/04/2013	30/04/2012
		$$'000	$$'000	$$'000	$$'000

1	Revenue	52	303	52	303
2	Profit/(loss) before tax	2,359	9	2,359	9
3	Profit/(loss) for the period	2,359	9	2,359	9
4	Profit/(loss) attributable to ordinary equity holders of the parent	2,385	12	2,385	12
5	Basic earnings/(loss) per share (Subunit)	0.62	0.00	0.62	0.00
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.0594		0.0531

icy97

ASIA BIOENERGY TECHNOLOGIES BERHAD

Particulars of Substantial Securities Holder

Name	The Goldman Sachs Group, Inc.
Address	Corporation Trust Center, 1209 Orange Street, Wilmington, New Castle County, Delaware 19801, United States of America
NRIC/Passport No/Company No.	2923466
Nationality/Country of incorporation	United States of America
Descriptions (Class & nominal value)	Ordinary Shares of RM0.10 each
Name & address of registered holder	Goldman Sachs International ("GSI") Peterborough Court, 133 Fleet Street, London EC4A 2BB, United Kingdom

Date interest acquired & no of securities acquired
Currency	Malaysian Ringgit (MYR)
Date interest acquired	14/06/2013
No of securities	20,638,000
Circumstances by reason of which Securities Holder has interest	Indirect interest through open market acquisition of shares of Asia Bioenergy Technologies Berhad by GSI. GSI is a subsidiary of Goldman Sachs Holdings (U.K.), which is in turn a subsidiary of Goldman Sachs (UK) L.L.C. The Goldman Sachs Group, Inc. is the direct holding company of Goldman Sachs (UK) L.L.C. and the ultimate holding company of the other aforementioned entities.
Nature of interest	Indirect interest
Price Transacted ($$)
Total no of securities after change
Direct (units)
Direct (%)
Indirect/deemed interest (units)	20,638,000
Indirect/deemed interest (%)	5.4
Date of notice	21/06/2013

icy97

icy97 发表于 9-4-2013 02:23 AM

Biofutures 交易额变动 亚洲生化须股东批准

财经新闻 财经  2013-07-14 12:18
（吉隆坡13日讯）大马交易所拒绝亚洲生化（AsiaBio，0150，创业板）的申请，后者必须尽速针对与英国上市公司Biofutures国际股权交易数额变动一事，寻求股东批准。

亚洲生化去年杪献议与多名卖家透过换股方式，脱售Platinum Nanochem私人股权予Biofutures国际，而亚洲生化可以126万1123英镑（587万3049令吉）或每股0.06英镑的代价，换取Biofutures国际1.05%股权。

不过，马交所在今年4月时发信予亚洲生化，称该公司是以每股0.07英镑的价格，获得Biofutures国际的2101万8714股新普通股，认为亚洲生化脱售Platium Nanochem股权的金额，实则为147万1310英镑（685万1890令吉）。

有鉴于此，亚洲生化当时表示，将向马交所申请豁免针对交易数额的改变，而寻求股东批准的步骤。[南洋网财经]

ASIA BIOENERGY TECHNOLOGIES BERHAD

Type	Announcement
Subject	TRANSACTIONS (CHAPTER 10 OF LISTING REQUIREMENTS) NON RELATED PARTY TRANSACTIONS
Description	ASIA BIOENERGY TECHNOLOGIES BERHAD ("ASIABIO" OR THE "COMPANY") APPLICATION FOR A WAIVER FROM COMPLIANCE WITH PART D OF CHAPTER 10 OF THE LISTING REQUIREMENTS OF BURSA MALAYSIA SECURITIES BERHAD ("BURSA SECURITIES") FOR THE ACE MARKET IN RESPECT OF PROPOSALS TO DISPOSE OFF ASSETS THAT ARE PART OR WHOLE OF A LISTING EXERCISE ("APPLICATION")
We refer to our announcement on 8 April 2013. We wish to announce that the Company has received a letter from Bursa Malaysia Berhad dated 10 July 2013 on 12 July 2013. Bursa Securities had considered the Application and rejected the Application. However, Bursa Securities requires the Company to seek shareholders’ ratification for the revised consideration of the proposed disposal of 1,143,434 ordinary shares of RM1.00 each, representing 1.56% of the total ordinary shares, in Platinum Nanochem Sdn Bhd (formerly known as Platinum Energy Sdn Bhd) to Biofutures International PLC ("BIP") wherein the Company shall receive 21,018,714 new BIP shares i.e. a total consideration of ￡1,471,310 or RM6,851,890 instead as soon as possible. The Board of Directors will deliberate on the above matter and shall keep the shareholders informed of any development. This announcement is dated 12 July 2013.

icy97

中國私募基金看好東南亞潛能

大馬  2013-07-27 10:45
（吉隆坡26日訊）較早收購亞洲生物能源（ASIABIO,0150,創業板貿服組）13.08%股權的中國私募基金控股指出，他們看好東南亞區域發展潛能，特別是在農業及生物科技方面的潛能，是參股亞洲生物能源的主要原因。

糧食供應樞紐

中國私募基金控股委任陳石義為代表進駐亞洲生物能源董事部，並於今日首次在股東大會亮相。擔任執行董事的陳石義在股東大會後向媒體表示，中國的食品消費正在成長，而全球糧食供應儲備卻正在下滑，但大馬及其他區域國家是良好的糧食供應樞紐，因此將續在區域中尋求投資機會。

於此同時，亞洲生物能源執行董事呂金龍針對該公司的展望表示，該公司預期業務能夠取得雙位數成長，因生物科技業務發展良好。他透露，一些政府機構正測試該公司的生物科技產品且取得良好的效果，該機構位於吉打州的稻米不僅成功抵抗病毒且收成獲得增長，這激勵該公司更積極地推廣該生物科技產品。

未來展望方面，他表示該公司依然專注於投資科技領域，並持續在中國與美國物色良好潛能的科技公司。

“事實上，我們已經與中國郵政媒體聯號公司簽署備忘錄以參與後者的投資活動，包括發展互動媒體及提供付賬服務的互動小站。”

“這是我們進軍中國市場的第一步，此後還會續在中國尋找投資機會。”

他也提及，與宜鼎機械（AT,0072,創業板工業產品組））實業是生物科技業務擴張計劃之一。

“我們將為宜鼎機械提供能夠增加收成及加速分解廢物的科技與設計，而他們將負責製造機器並行銷至適合的市場。”（星洲日報／財經）


放眼盈利双数增长 亚洲生化拟引中美科技

财经新闻 财经  2013-07-27 12:54
（吉隆坡26日讯）亚洲生化（AsiaBio，0150，创业板）主席拿督黄顺伟认为，在生物科技业务前景看俏下，希望今年可录得双位数的盈利增长。

黄顺伟在公司股东常年大会结束后向媒体表示，公司正积极在中国、美国和各地寻找引入新科技以拓展业务。

“我们最新的木料生产计划即将在中国启动，机械也会在未来数月内送到。”

上述计划是以棕油树干为原料来生产木料，而且公司也已找到了来自国外的客户。

“我们非常看好这项计划的前景，也预计这可为公司带来可观的收入。”

原料价格挑战

他续称：“目前，我们手中还有数项计划正在进行中，而且进度良好。截至今年首季，我们成功录得了230万令吉的净利。”

黄顺伟由此设下目标，希望2013年盈收达到双位数的增长。

不过，由于公司核心业务是科技研发，所以每项投资都会损耗盈收。

“每项投资都会导致我们的财务波动不稳，原料价格也是一个挑战。不过我们拥有强稳的客源和业务，所以这都不是大问题。”

出席股东大会后记者会的高层，包括了亚洲生化执行董事吕金龙和执行董事陈石义。

Biofutures交易额变动 将召开特大表决

针对亚洲生化与英国上市公司Biofutures国际股权交易数额变动一事，吕金龙表示，将于数月后召开股东特别大会，寻求股东批准有关数额变动。

亚洲生化去年杪献议以换股方式脱售旗下Platinum Nanochem私人有限公司股权予Biofutures国际，而亚洲生化可以126万1123英镑（587万3049令吉）或每股0.06英镑的代价，换取Biofutures国际1.05%股权。

不过，马交所在今年4月时发信予亚洲生化，称该公司是以每股0.07英镑，相等于685万1890令吉的价格，获得Biofutures国际的2101万8714股新普通股，因而要求公司寻求股东批准交易数额变动。

交易已经完成

吕金龙表示：“事实上，我们和Biofutures国际的交易已经完成，但我们还是需要召开特大，让股东表决交易数额变动一事。”

无论如何，他表示这并不会为公司带来影响。

“最坏的情况是股东反对，但我们就会退还多余的数额或股权。但是股权互换活动已经完成，所以不会带来显著影响。”[南洋网财经]

icy97

Notice of Interest Sub. S-hldr (29A)

ASIA BIOENERGY TECHNOLOGIES BERHAD

Particulars of Substantial Securities Holder

Name	The Goldman Sachs Group, Inc. ("TGSGI")
Address	Corporation Trust Center, 1209 Orange Street, Wilmington, New Castle County, Delaware 19801, United States of America
NRIC/Passport No/Company No.	2923466
Nationality/Country of incorporation	United States of America
Descriptions (Class & nominal value)	Ordinary Shares of RM0.10 each
Name & address of registered holder	Goldman Sachs International ("GSI") Peterborough Court, 133 Fleet Street, London EC4A 2BB, United Kingdom

Date interest acquired & no of securities acquired
Currency	Malaysian Ringgit (MYR)
Date interest acquired	15/08/2013
No of securities	22,159,500
Circumstances by reason of which Securities Holder has interest	Indirect interest through open market acquisition of shares of Asia Bioenergy Technologies Berhad by GSI. GSI is a subsidiary of Goldman Sachs Holdings (U.K.), which is a subsidiary of Goldman Sachs Group Holdings (U.K.), which is in turn a subsidiary of Goldman Sachs (UK) L.L.C. TGSGI is the direct holding company of Goldman Sachs (UK) L.L.C. and the ultimate holding company of the other aforementioned entities.
Nature of interest	Indirect interest
Price Transacted ($$)
Total no of securities after change
Direct (units)
Direct (%)
Indirect/deemed interest (units)	22,159,500
Indirect/deemed interest (%)	5.27
Date of notice	22/08/2013

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 31/07/2013

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31/07/2013	31/07/2012	31/07/2013	31/07/2012
		$$'000	$$'000	$$'000	$$'000

1	Revenue	612	790	664	1,093
2	Profit/(loss) before tax	-1,377	-1,802	938	-1,793
3	Profit/(loss) for the period	-1,377	-1,802	938	-1,793
4	Profit/(loss) attributable to ordinary equity holders of the parent	-1,347	-1,787	994	-1,775
5	Basic earnings/(loss) per share (Subunit)	-0.32	-0.47	0.24	-0.46
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.0598		0.0531

icy97

亞洲生物能源籌4202萬

2013-09-24 11:42      
（吉隆坡23日訊）亞洲生物能源（ASIABIO,0150,創業板貿服組）擬以1配1送1憑單比例配售附加股，籌資最多4千202萬令吉作為科技孵化基金和營運資本。

該公司發文告表示，建議以1配1附加股，發售最高4億2千零20萬股附加股，發售價為每股10仙，相等於截至2013年9月20日止5日成交量加權市價12仙折價5.66%，料可籌資最多4千202萬令吉，其中4千102萬令吉作為科技孵化基金，營運資本和企業活動開銷則各為50萬令吉。

隨後，亞洲生物能源將以1附加股送1憑單比例，派送最高4億2千零20萬單位憑單，行使價為每單位10仙，相等於截至2013年9月20日止5日成交量加權市價12仙折價16.67%；若所有憑單獲得轉換，公司料可籌集最高4千202萬令吉，將用作資本開銷、投資機會和營運資本。

在完成相關計劃後，公司繳足資本將從4千202萬令吉擴大至最高1億2千606萬令吉，雖不會對截至2014年1月31日止財政年盈利帶來重大影響，但額外資金投資和營運資本將為未來盈利帶來正面效益。

大股東同意認購至少5千萬股

該公司大股東、中國私募基金成長資金（C P EGrowth Capital）已同意認購至少5千萬股附加股，總值約500萬令吉，以達到附加股計劃展開的門檻。（星洲日報／財經）

ASIA BIOENERGY TECHNOLOGIES BERHAD

Type	Announcement
Subject	NEW ISSUE OF SECURITIES (CHAPTER 6 OF LISTING REQUIREMENTS) FUND RAISING
Description	ASIA BIOENERGY TECHNOLOGIES BERHAD (“ASIABIO” OR THE “COMPANY”) PROPOSED RIGHTS ISSUE WITH WARRANTS
On behalf of the Board of Directors of AsiaBio, M&A Securities Sdn Bhd wishes to announce that AsiaBio proposes to undertake a renounceable rights issue of up to 420,200,000 new ordinary shares of RM0.10 each in AsiaBio (“Rights Shares”) together with up to 420,200,000 new free detachable warrants (“Warrants”) at an issue price of RM0.10 per Rights Share on the basis of one (1) Rights Share together with one (1) Warrant for every one (1) existing ordinary share of RM0.10 held in AsiaBio (“Proposed Rights Issue with Warrants”). Kindly refer to the attachment for more information on the Proposed Rights Issue with Warrants. This announcement is dated 23 September 2013

Attachments Asia Bio - Announcement.pdf

icy97

icy97 发表于 11-6-2013 01:30 AM
亚洲生化与OVG及CPM签约 合作推出互动媒体平台

财经新闻 财经  2013-06-12 11:20

亚洲生化终止合作计划

财经新闻 财经  2013-10-06 09:10
（吉隆坡5日讯）亚洲生化（ASIABIO，0150，创业板）与Omni Ventures Global有限公司（简称OVG）和Hunan China Post Media有限公司（简称CPM）的互动媒体平台计划宣布终止。

该公司昨天向马交所报备，已在9月20日致函通知两家公司，无意跟进早前签署的意向备忘录，决定终止合作。

亚洲生化是在今年6月，与OVG和CPM签署意向备忘录，共同草拟合作推出互动媒体平台的合约内容。

报备文件指出，该公司已在截至2013年7月31日财年的财报中，告知终止合作事宜。[南洋网财经]

ASIA BIOENERGY TECHNOLOGIES BERHAD

Type	Announcement
Subject	OTHERS
Description	ASIA BIOENERGY TECHNOLOGIES BERHAD (“ASIABIO” OR THE “COMPANY”) TERMINATION OF THE MEMORANDUM OF INTENT BETWEEN THE COMPANY, OMNI VENTURES GLOBAL LTD AND HUNAN CHINA POST MEDIA LIMITED (“CPM”) FOR COLLABORATION AND INVESTMENT INTO CPM
With reference to the Company’s announcements on 10 June 2013 and 10 September 2013 on the Memorandum of Intent between the Company, Omni Ventures Global Ltd and Hunan China Post Media Limited (hereinafter referred to as “MOI”), we wish to announce that the Company has decided against pursuing the MOI and has duly sent a notice of termination on 20 September 2013. The termination of the MOI was disclosed in note B10 (Status of Corporate Proposal) in the Company’s quarterly report on results for the 2nd Quarter ended 31 July 2013. This announcement is dated 4 October 2013.

icy97

ASIA BIOENERGY TECHNOLOGIES BERHAD

Type	Announcement
Subject	OTHERS
Description	ASIA BIOENERGY TECHNOLOGIES BERHAD (“ASIABIO” OR THE “COMPANY”) TERMINATION OF THE MEMORANDUM OF INTENT BETWEEN THE COMPANY, OMNI VENTURES GLOBAL LTD AND HUNAN CHINA POST MEDIA LIMITED (“CPM”) FOR COLLABORATION AND INVESTMENT INTO CPM (“MOI”)
We refer to the Company’s announcement on 4 October 2013 pertaining to the termination of the MOI. We wish to inform that the MOI provides for a due diligence to be conducted by the Company. Further to the signing of the MOI, the Company had conducted a preliminary due diligence which found that the project involving the launch of interactive media platform has not fully met the investment criteria set out by the Company. Thus, the Company terminated the MOI This announcement is dated 7 October 2013.

lengleng28

不是说取消了计划吗？怎么还上十大？

icy97

icy97 发表于 27-3-2013 01:01 AM

Type	Announcement
Subject	TRANSACTIONS (CHAPTER 10 OF LISTING REQUIREMENTS) NON RELATED PARTY TRANSACTIONS
Description	ASIA BIOENERGY TECHNOLOGIES BERHAD (“ASIABIO” OR “THE COMPANY”) PROPOSED DISPOSAL OF 1,143,434 ORDINARY SHARES OF RM1.00 EACH, REPRESENTING 1.56% OF THE TOTAL ORDINARY SHARES, IN PLATINUM NANOCHEM SDN BHD (FORMERLY KNOWN AS PLATINUM ENERGY SDN BHD) (“PNSB”) TO GRAPHENE NANOCHEM PLC (FORMERLY KNOWN AS BIOFUTURES INTERNATIONAL PLC) (“GN”) (“PROPOSAL”)
Reference is made to the Company’s announcement on 26 March 2013 on the Proposal. We wish to announce that the Company has on 14 October 2013 received a notice from Total Platinum Holdings Sdn Bhd (“TPHSB”), the main promoter of PNSB, for the termination of the call option agreement that was previously executed between TPHSB and the Company on 18 February 2013. With the termination of the call option agreement, TPHSB will no longer have the 12-month option to acquire the 21,018,714 new ordinary shares of GN issued to the Company pursuant to the Proposal, at the price of £0.06 per share. The termination of the call option agreement was made in view of the on-going efforts by both parties to collaborate to expand PNSB’s products reach into new markets. This announcement is dated 14 October 2013.

chinesesp

icy97 发表于 15-10-2013 03:57 AM

为何“PROPOSED DISPOSAL OF 1,143,434 ORDINARY SHARES OF RM1.00 EACH, REPRESENTING 1.56% OF THE TOTAL ORDINARY SHARES, IN PLATINUM NANOCHEM SDN BHD“会造成大跌。。。。低价售股？？主要业务？？

williamnkk81

chinesesp 发表于 13-5-2013 02:28 PM
@williamnkk81
如何看待这公司？？早前CPE GrowthCapital购入巴迪玛斯（Patimas，7042，主板科技股）近5. ...

對不起。。 版主現在通知我的。。 我可以講的是。。 會是投機的活動比較大。。。 基本面沒什麼作為。。。

williamnkk81

chinesesp 发表于 15-10-2013 11:06 AM
为何“PROPOSED DISPOSAL OF 1,143,434 ORDINARY SHARES OF RM1.00 EACH, REPRESENTING 1.56% OF THE TOTAL ...

沒有關係的。。。 市場變動罷了。。。。

icy97

Notice of Interest Sub. S-hldr (29A)

ASIA BIOENERGY TECHNOLOGIES BERHAD

Particulars of Substantial Securities Holder

Name	Deutsche Bank AG
Address	12 Taunusanlage, 60325 Frankfurt am Main, Hessen, Germany
NRIC/Passport No/Company No.	HRB30000
Nationality/Country of incorporation	Germany
Descriptions (Class & nominal value)	Ordinary Shares of RM0.10 each
Name & address of registered holder	DB (Malaysia) Nominee (Asing) Sdn Bhd Deutsche Bank (M) Berhad Level 20, Menara IMC 8, Jalan Sultan Ismail 50250 Kuala Lumpur

Date interest acquired & no of securities acquired
Currency	Malaysian Ringgit (MYR)
Date interest acquired	18/10/2013
No of securities	21,975,000
Circumstances by reason of which Securities Holder has interest	Acquisition of shares in open market
Nature of interest	Indirect
Price Transacted ($$)
Total no of securities after change
Direct (units)
Direct (%)
Indirect/deemed interest (units)	21,975,000
Indirect/deemed interest (%)	5.23
Date of notice	25/10/2013

icy97

宜鼎成立公司聯營生物質處理科技業務

2013-11-12 17:08      
（吉隆坡12日訊）宜鼎機械（AT，0072，創業板工業產品組）透過成立Yellow Choice公司與亞洲生物能源（ASIABIO，0150，創業板貿服組）合作經營生物質處理科技業務。

宜鼎機械發文告表示，Yellow Choice的繳足資本為10萬令吉，其中該公司佔81%股權，亞洲生物能源則擁有19%股權。

此外，兩家公司的合作促使宜鼎機械可多元化業務至製造具有生物質堆肥或再氣化功能的生物質處理裝備。（星洲日報／財經）

ASIA BIOENERGY TECHNOLOGIES BERHAD

Type	Announcement
Subject	TRANSACTIONS (CHAPTER 10 OF LISTING REQUIREMENTS) NON RELATED PARTY TRANSACTIONS
Description	ASIA BIOENERGY TECHNOLOGIES BERHAD (“ASIABIO” OR THE “COMPANY”) SHAREHOLDERS’ AGREEMENT BETWEEN AT SYSTEMATIZATION BERHAD AND ASIABIO IN RELATION TO THE SET UP OF BIOMASS PROCESSING TECHNOLOGIES BUSINESS UNIT VIA YELLOW CHOICE SDN BHD
The details of the announcement is attached herein. This announcement is dated 11 November 2013.

Attachments ABT - Announcement dated 11 Nov 2013 (Shareholders' Agreement with AT).pdf

lengleng28

终于起会我的价位了

Clip2

lengleng28 发表于 13-11-2013 09:17 AM
终于起会我的价位了

然后？卖了吗？ 价钱又跌回了。。。

lengleng28

Clip2 发表于 13-11-2013 12:26 PM
然后？卖了吗？ 价钱又跌回了。。。

还没有，再看看。。